AllianceBernstein
FHTX icon

AllianceBernstein’s Foghorn Therapeutics FHTX Stock Holding History

AllianceBernstein’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
29,760
+3,100
+12% +$13.8K ﹤0.01% 3216
2026
Q1 		$144K Hold
26,660
– – ﹤0.01% 3118
2025
Q4 		$144K Hold
26,660
– – ﹤0.01% 3126
2025
Q3 		$130K Buy
26,660
+1,610
+6% +$8.54K ﹤0.01% 3152
2025
Q2 		$118K Buy
25,050
+7,670
+44% +$32.1K ﹤0.01% 3151
2025
Q1 		$63.4K Hold
17,380
– – ﹤0.01% 3110
2024
Q4 		$82K Hold
17,380
– – ﹤0.01% 3143
2024
Q3 		$162K Buy
17,380
+2,790
+19% +$20.2K ﹤0.01% 3066
2024
Q2 		$83.9K Buy
14,590
+4,540
+45% +$27K ﹤0.01% 3136
2024
Q1 		$67.4K Hold
10,050
– – ﹤0.01% 3062
2023
Q4 		$64.8K Sell
10,050
-700
-7% -$3.02K ﹤0.01% 3111
2023
Q3 		$53.8K Buy
10,750
+690
+7% +$5.32K ﹤0.01% 3132
2023
Q2 		$70.8K Buy
+10,060
New +$70.3K ﹤0.01% 3108

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

AllianceBernstein's FHTX Position: Q2 2026 in Review

AllianceBernstein increased its Foghorn Therapeutics (FHTX) stake by 12% in Q2 2026, buying an estimated $13.8K and bringing the position to 29,760 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #3216.

AllianceBernstein first reported a position in FHTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $162K in Q3 2024. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • AllianceBernstein held 29,760 shares of Foghorn Therapeutics worth $142K as of Q2 2026.
  • AllianceBernstein bought 3,100 Foghorn Therapeutics shares in Q2 2026, an estimated $13.8K.
  • Foghorn Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3216 holding.
  • AllianceBernstein first reported a position in Foghorn Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • AllianceBernstein's Foghorn Therapeutics position peaked at $162K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.